Géraud Forestier

Géraud Forestier

Auto-generated profile, based on publicly available information

Géraud Forestier

Department of Neuroradiology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Radiology
Verified
Journal Article
Closed access
SKStéphane Kremer
Stéphane Kremer
FLFrançois Lersy
François Lersy
JSJérome de Sèze
Jérome de Sèze
JFJean-Christophe Ferré
Jean-Christophe Ferré
AMAdel Maamar
Adel Maamar
FCFrancois Cotton
Francois Cotton
Background Brain MRI parenchymal signal abnormalities have been in association with SARS-CoV-2. Purpose Describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe COVI...

29 September 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
SKStéphane Kremer
Stéphane Kremer
FLFrançois Lersy
François Lersy
MAMathieu Anheim
Mathieu Anheim
HMHamid Merdji
Hamid Merdji
MSMaleka Schenck
Maleka Schenck
FCFrancois Cotton
Francois Cotton
Objective To describe neuroimaging findings and to report the epidemiologic and clinical characteristics of patients with coronavirus disease 2019 (COVID-19) with neurologic manifestations. Methods In this retrospective multicenter study (11 hospitals), we included 64 patients with confirmed COVID-19 with neurologic manifestations who underwent a brain MRI. Results The cohort included 43 men (67%) and 21 women (33%); their median age was 66 (range 20–92) years. Thirty-six (56%) brain MRIs were considered abnormal, possibly related to severe acute respiratory syndrome coronavirus. Ischemic strokes (27%), leptomeningeal enhancement (17%), and encephalitis (13%) were the most frequent neuroimaging findings. Confusion (53%) was the most common neurologic manifestation, followed by impaired consciousness (39%), presence of clinical signs of corticospinal tract involvement (31%), agitation (31%), and headache (16%). The profile of patients experiencing ischemic stroke was different from that of other patients with abnormal brain imaging: the former less frequently had acute respiratory distress syndrome (p = 0.006) and more frequently had corticospinal tract signs (p = 0.02). Patients with encephalitis were younger (p = 0.007), whereas agitation was more frequent for patients with leptomeningeal enhancement (p = 0.009). Conclusions Patients with COVID-19 may develop a wide range of neurologic symptoms, which can be associated with severe and fatal complications such as ischemic stroke or encephalitis. In terms of meningoencephalitis involvement, even if a direct effect of the virus cannot be excluded, the pathophysiology seems to involve an immune or inflammatory process given the presence of signs of inflammation in both CSF and neuroimaging but the lack of virus in CSF. ClinicalTrials.gov identifier NCT04368390.

1 June 2024 in European Stroke Journal
Verified
Journal Article
Closed access
Adam DmytriwAdam Dmytriw
Adam Dmytriw
BMBasel Musmar
Basel Musmar
Hamza A SalimHamza A Salim
Hamza A Salim
SGSherief Ghozy
Sherief Ghozy
JSJames E Siegler
James E Siegler
AGAdrien Guenego
Adrien Guenego
Background: Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO), but its efficacy and safety in medium vessel occlusion (MeVO) remain less explored. This multicenter, retrospective study aims to investigate the incidence and clinical outcomes of vessel perforations (confirmed by extravasation during an angiographic series) during MT for AIS caused by MeVO. Methods: Data were collected from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. A total of 1373 AIS patients with MeVO underwent MT. Baseline characteristics, procedural details, and clinical outcomes were analyzed. Results: The incidence of vessel perforation was 4.8% (66/1373). Notably, our analysis indicates variations in perforation rates across different arterial segments: 8.9% in M3 segments, 4.3% in M2 segments, and 8.3% in A2 segments (p = 0.612). Patients with perforation had significantly worse outcomes, with lower rates of favorable angiographic outcomes (TICI 2c-3: 23% vs 58.9%, p < 0.001; TICI 2b-3: 56.5% vs 88.3%, p < 0.001). Functional outcomes were also worse in the perforation group (mRS 0–1 at 3 months: 22.7% vs 36.6%, p = 0.031; mRS 0–2 at 3 months: 28.8% vs 53.9%, p < 0.001). Mortality was higher in the perforation group (30.3% vs 16.8%, p = 0.008). Conclusion: This study reveals that while the occurrence of vessel perforation in MT for AIS due to MeVO is relatively rare, it is associated with poor functional outcomes and higher mortality. The findings highlight the need for increased caution and specialized training in performing MT for MeVO. Further prospective research is required for risk mitigation strategies.

14 March 2022 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
JCJildaz Caroff
Jildaz Caroff
LALaurent Aubert
Laurent Aubert
CLCécile Lavenu-Bombled
Cécile Lavenu-Bombled
SFSamy Figueiredo
Samy Figueiredo
KHKamelia Habchi
Kamelia Habchi
BKBasile Kerleroux
Basile Kerleroux
Background Neurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity in antithrombotic use between centers. Through a nationwide survey, we aimed to obtain an exhaustive cross-sectional overview of antithrombotic use in neurointerventional procedures in France. Methods In April 2021, French neurointerventional surgery centers were invited to participate in a nationwide 51-question survey disseminated through an active trainee-led research collaborative network (the JENI-RC). Results All 40 centers answered the survey. Fifty-one percent of centers reported using ticagrelor and 43% used clopidogrel as premedication before intracranial stenting. For flow diversion treatment, dual antiplatelet therapy was maintained for 3 or 6 months in 39% and 53% of centers, respectively, and aspirin was prescribed for 12 months or more than 12 months in 63% and 26% of centers, respectively. For unruptured aneurysms, the most common heparin bolus dose was 50 IU/kg (59%), and only 35% of centers monitored heparin activity for dose adjustment. Tirofiban was used in 64% of centers to treat thromboembolic complications. Fifteen percent of these comprehensive stroke centers reported using tenecteplase to treat acute ischemic strokes. Cangrelor appeared as an emergent drug in specific indications. Conclusion This nationwide survey highlights the important heterogeneity in clinical practices across centers. There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field.

1 March 2024 in European Stroke Journal
Verified
Journal Article
Open access
RRRazvan Alexandru Radu
Razvan Alexandru Radu
VCVincent Costalat
Vincent Costalat
RFRobert Fahed
Robert Fahed
SGSherief Ghozy
Sherief Ghozy
JSJames E. Siegler
James E. Siegler
AGAdrien Guenego
Adrien Guenego
Introduction: First pass effect (FPE), achievement of complete recanalization (mTICI 2c/3) with a single pass, is a significant predictor of favorable outcomes for endovascular treatment (EVT) in large vessel occlusion stroke (LVO). However, data concerning the impact on functional outcomes and predictors of FPE in medium vessel occlusions (MeVO) are scarce. Patients and Methods: We conducted an international retrospective study on MeVO cases. Multivariable logistic modeling was used to establish independent predictors of FPE. Clinical and safety outcomes were compared between the two study groups (FPE vs non-FPE) using logistic regression models. Good outcome was defined as modified Rankin Scale 0–2 at 3 months. Results: Eight hundred thirty-six patients with a final mTICI ⩾ 2b were included in this analysis. FPE was observed in 302 patients (36.1%). In multivariable analysis, hypertension (aOR 1.55, 95% CI 1.10–2.20) and lower baseline NIHSS score (aOR 0.95, 95% CI 0.93–0.97) were independently associated with an FPE. Good outcomes were more common in the FPE versus non-FPE group (72.8% vs 52.8%), and FPE was independently associated with favorable outcome (aOR 2.20, 95% CI 1.59–3.05). 90-day mortality and intracranial hemorrhage (ICH) were significantly lower in the FPE group, 0.43 (95% CI, 0.25–0.72) and 0.55 (95% CI, 0.39–0.77), respectively. Conclusion: Over 2/3 of patients with MeVOs and FPE in our cohort had a favorable outcome at 90 days. FPE is independently associated with favorable outcomes, it may reduce the risk of any intracranial hemorrhage, and 3-month mortality.

1 August 2024 in Radiology
Verified
Journal Article
Closed access
Adam DmytriwAdam Dmytriw
Adam Dmytriw
SGSherief Ghozy
Sherief Ghozy
Hamza A SalimHamza A Salim
Hamza A Salim
BMBasel Musmar
Basel Musmar
JSJames E. Siegler
James E. Siegler
TCThe MAD-MT Consortium
The MAD-MT Consortium
This international multicenter study found that adjunctive intravenous thrombolysis may not provide benefit to mechanical thrombectomy in patients with acute ischemic stroke caused by distal and medium vessel occlusion.